The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Interim results of the ProMMise trial: belantamab + cyclophosphamide & dexamethasone in R/R myeloma
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, presents the interim results from cohort B of the UK Myeloma Research Alliance ProMMise clinical trial, highlighting the efficacy and tolerability of belantamab mafodotin in combination with cyclophosphamide and dexamethasone for patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Popat notes that the lower dose of belantamab is associated with a higher response rate and better tolerability profile, making it an efficacious and convenient treatment option for patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
